**Nontuberculous Mycobacterial Lung Disease (NTM-LD):   
Individualizing Treatment Goals and Strategies**

|  |  |
| --- | --- |
| Resource | Address |
| Schiff HF, et al. **Clinical relevance of non-tuberculous mycobacteria isolated from respiratory specimens: seven year experience in a UK hospital.** *Sci Rep*. 2019;9:1730. | <https://pubmed.ncbi.nlm.nih.gov/30741969/> |
| Irwin RS, et al. **Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report.** *CHEST.* 2018;153:196-209. | <https://pubmed.ncbi.nlm.nih.gov/29080708/> |
| Ahmed I, et al. **Non-tuberculous mycobacterial infections-A neglected and emerging problem.** *Int J Infect Dis*. 2020;92S:S46-S50. | <https://pubmed.ncbi.nlm.nih.gov/32114200/> |
| Koh EJ, et al. **Outcomes of *Mycobacterium avium* complex lung disease based on clinical phenotype.** *Eur Respir J*. 2017;50:1602503. | <https://pubmed.ncbi.nlm.nih.gov/28954780/> |
| Daley CL, et al. **Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.** *Clin Infect Dis.* 2020;71:905-913. | <https://pubmed.ncbi.nlm.nih.gov/32797222/> |
| Hwang JA, et al. **Natural history of *Mycobacterium avium* complex lung disease in untreated patients with stable course.** *Eur Respir J*. 2017;49:1600537. | <https://pubmed.ncbi.nlm.nih.gov/28275170/> |
| Kwon BS, et al. **The natural history of non-cavitary nodular bronchiectatic *Mycobacterium avium* complex lung disease.** *Resp Med.* 2019;150:45-50. | <https://pubmed.ncbi.nlm.nih.gov/30961950/> |
| Moon SM, et al. **Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease.** *Resp Med.* 2019;151:1-7. | <https://pubmed.ncbi.nlm.nih.gov/31047103/> |
| Jeong BH, et al. **Intermittent antibiotic therapy for nodular bronchiectatic *Mycobacterium avium* complex lung disease.** *Am J Resp Crit Care Med.* 2015;191:96-103. | <https://pubmed.ncbi.nlm.nih.gov/25393520/> |
| Griffith DE, et al. **Semiquantitative Culture Analysis during Therapy for *Mycobacterium avium* Complex Lung Disease.** *Am J Respir Crit Care Med.* 2015;192:754-760. | <https://pubmed.ncbi.nlm.nih.gov/26068042/> |
| Moon SM, et al. **Unresolved issues in treatment outcome definitions for nontuberculous mycobacterial pulmonary disease.** *Euro Respir J.* 2019;53:1801636. | <https://pubmed.ncbi.nlm.nih.gov/30819812/> |
| Griffith D, et al. **Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by *Mycobacterium avium* Complex (CONVERT). A Prospective, Open-Label, Randomized Study.** *Am J Respir Crit Care Med*. 2018;198:1559-1569. | <https://pubmed.ncbi.nlm.nih.gov/30216086/> |
| Kamii Y, et al. **Adverse reactions associated with long-term drug administration in *Mycobacterium avium* complex lung disease.** *Int J Tuberc Lung Dis.* 2018;22:1505-1510. | <https://pubmed.ncbi.nlm.nih.gov/30606324/> |
| Swenson C, et al. Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey. *Open Forum Infect Dis*. 2020;7:ofaa079. | <https://pubmed.ncbi.nlm.nih.gov/32322600/> |